Boston Business Journal reports that Alnylam will layoff 52 employees (previously discussed as a restructuring program) on March 23rd. This 33% trimming of the staff will contribute to savings of approximately $20 M. Layoffs will include positions for Senior Director of Biotherapics, Senior Director of Business Development, Senior Director of Pharma Operations, and a Senior Director for IT -- along with 9 senior scientists and 14 research associates among the casualties. The one time employee costs of termination will be on order of $4 M.
See what happens when most of Big Pharma gives up on RNAi -- at least for now.
Posted by Bruce Lehr Feb 16th 2012.